These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3548734)

  • 1. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.
    Mellies MJ; Stein EA; Khoury P; Lamkin G; Glueck CJ
    Atherosclerosis; 1987 Jan; 63(1):57-64. PubMed ID: 3548734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
    Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
    Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Stohler R; Keller U; Riesen WF
    Eur J Clin Pharmacol; 1989; 37(2):199-203. PubMed ID: 2507323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
    Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P
    Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate affects the compositions of lipoproteins.
    Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
    Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Camare R; Luc G; Ziegler O; Dachet C; Bruckert E; Douste-Blazy P; Drouin P; Jacotot B
    Metabolism; 1992 May; 41(5):498-503. PubMed ID: 1588829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P; Celis H; Desager JP; Fagard R
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
    Ziegler O; Drouin P
    Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
    Rouffy J; Chanu B; Bakir R; Djian F; Goy-Loeper J
    Atherosclerosis; 1985 Mar; 54(3):273-81. PubMed ID: 3994783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia.
    Weisweiler P
    Metabolism; 1989 Mar; 38(3):271-4. PubMed ID: 2918846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
    Lussier-Cacan S; Bard JM; Boulet L; Nestruck AC; Grothé AM; Fruchart JC; Davignon J
    Atherosclerosis; 1989 Aug; 78(2-3):167-82. PubMed ID: 2783201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.